Physician profile
Thomas E Scott
NPI 1205898913
$47,582.86
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $12K · 2021: $4,328 · 2022: $100.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $14,179.44 | 2019 | |
| Pfizer INC. | $12,412.24 | 2019-2021 | |
| Amgen INC. | $12,137.05 | 2019-2022 | |
| Abbvie INC. | $7,061.52 | 2019-2022 | |
| Ucb, INC. | $1,295.00 | 2020 | |
| Lilly USA, LLC | $167.52 | 2019-2021 | |
| Janssen Biotech, INC. | $99.30 | 2019-2021 | |
| Glaxosmithkline, LLC. | $63.15 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.57 | 2019 | |
| Horizon Therapeutics Plc | $45.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.23 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $21.24 | 2019 | |
| Covidien Lp | $18.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.